Skip to main content

Table 3 Comparison of patients with and without atherosclerotic plaques

From: Methotrexate use, not interleukin 33, is associated with lower carotid intima-media thickness in patients with rheumatoid arthritis

Variable Plaques absent
(n = 78)
Plaques present
(n = 24)
p-value
Age (years - mean ± SD) 54.2 ± 9.8 59.9 ± 9.7 0.014a
Disease length (years - mean ± SD) 16.3 ± 9.7 21.9 ± 8 0.011a
Postmenopausal (n (%)): No
Yes
21 (91.3)
50 (70.4)
2 (8.7)
21 (29.6)
0.043b
LDL within goal (Ref. 65) (n (%)) No
Yes
56 (70)
22 (100)
24 (30)
0 (0)
0.003b
Global CVR score (median (IQR)) 6.3 (2.9–11.6) 8.7 (6.2–11.8) 0.048c
IMT (mm - median (IQR)) 0.6 (0.6–0.8) 0.8 (0.7–0.9) 0.001c
IL-33 (n (%))d: positive
negative
52 (76.5)
26 (76.5)
16 (23.5)
8 (23.5)
1b
IL-33 (pg/mL - median (IQR))e 33.1 (0–78.7) 12.1 (0–85.8) 0.856c
IL-33 (pg/mL - median (IQR))f 69.1 (33.1–124.3) 70.6 (12.1–90.1) 0.745c
sST2 (pg/mL - median (IQR))g 461.7 (316.6–651) 485.9 (372.9–649) 0.675c
IL-33/sST2 (median (IQR))h 0.1 (0–0.3) 0.1 (0–0.3) 0.965c
  1. at-test; bchi-square; cMann-Whitney test
  2. SD standard deviation, NPJ number of painful joints upon physical examination, IQR interquartile range, SAH systemic arterial hypertension, CVR cardiovascular risk, NSAIDs nonsteroidal anti-inflammatory drugs; and IMT intima-media thickness
  3. dIL-33 positive: serum IL-33 ≥ 23.4 pg/mL; and IL-33 negative: serum IL-33 < 23.4 pg/mL
  4. elevels below the limit of detection were considered as zero
  5. fonly considering the 68 participants with levels above the limit of detection
  6. gdata from the 101 participants with detectable levels
  7. hIL-33-to-sST2 ratio